Electroporation Gene Delivery for Consistent Recombinant Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating recombinant proteins in mammalian cells face challenges such as cell toxicity, batch-to-batch inconsistency, unstable expression, improper localization, and inadequate post-translational modification, particularly when expressing drug metabolizing enzymes and transporters.
Innovation Solution
The method involves electroporation-mediated gene delivery into mammalian cells, specifically using nucleic acids encoding membrane-bound proteins or drug metabolizing enzymes, followed by culturing and isolating cell membranes or fractions, which ensures correct post-translational modifications and targeted localization, thereby improving protein expression and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional transfection methods (calcium phosphate precipitation, microinjection, lipofection) are used to introduce nucleic acid constructs into mammalian cells, then gene delivery can be achieved, but cell toxicity occurs and expression levels show significant batch-to-batch inconsistency
Solution Approach 1:
The patent changes the physical parameters of gene delivery by using electroporation with specific voltage pulses (e.g., 25V for 5ms) instead of chemical transfection methods. This physical parameter change enables consistent high-level expression of recombinant proteins while maintaining cell viability, resolving the contradiction between expression reliability and cell toxicity
Solution Approach 2:
The patent replaces chemical transfection mechanisms (calcium phosphate precipitation, lipofection) with an electrical field-based electroporation system. This substitution eliminates the harmful chemical interactions that cause cell toxicity while achieving reliable, consistent gene delivery and protein expression
2Quantity of substance
If selection schemes with amplifiable markers are used to amplify introduced nucleic acid constructs, then expression levels can be increased, but the process becomes complex and expression stability decreases
Solution Approach 1:
The patent extracts and eliminates the complex selection and amplification steps from the transfection process. By using electroporation to achieve direct, high-efficiency gene delivery, the method obtains high protein expression levels without requiring additional selection markers or multi-step amplification procedures, thereby reducing process complexity
Solution Approach 2:
The patent performs the gene delivery action in advance with a single electroporation step that achieves sufficient expression levels directly, eliminating the need for subsequent selection and amplification steps. This preliminary high-efficiency delivery prevents the need for complex follow-up procedures
3Reliability
If episomal vectors are used for transfection, then gene delivery can be achieved, but proper localization, post-translational modification, and protein folding are compromised
Solution Approach 1:
The patent changes the culture conditions following electroporation, including using serum-free media with specific supplements (insulin, transferrin, selenium) and controlling culture duration (48-72 hours). These parameter changes ensure proper cellular environment for protein synthesis, localization, and post-translational modification while maintaining the simplicity of the overall process
Solution Approach 2:
The patent maintains continuous optimization of culture conditions after electroporation to ensure sustained proper protein folding and modification. By controlling culture parameters throughout the expression period, the method ensures consistent production of properly localized and modified proteins without complicating the manufacturing process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides consistent and active recombinant protein expression with reduced batch-to-batch variation and increased activity, enabling more 'human-like' protein performance compared to existing systems, and significantly reduces development time for drug metabolizing enzyme and transporter microsome/cytosolic fractions.
Implementation Method 1
electroporating the mammalian cell such that the nucleic acid enters said mammalian cell
Data Source
AI summary
The present disclosure relates to method and compositions for generating proteins. In particular, the present disclosure relates to electroporation mediated gene delivery in the generation of recombinant proteins (e.g., drug metabolizing enzyme and transporter vesicles) in mammalian cells.